Mark Hurtt, M.D., Acting Chief Medical Officer Oct. 11 | 9:45am | Ecolab Life Sciences Ballroom Wakefield, MA (Private) Myrtelle Inc. is a gene therapy company focused on developing transformative treatments for neurodegenerative diseases. The company has a proprietary platform, intellectual property, and portfolio of programs and technologies supporting...
Adrienne Farid, Ph.D., Chief Operating Officer Oct. 11 | 4:30pm | Ecolab Life Sciences Ballroom Philadelphia, PA (NASDAQ: IPSC) Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation...
Michael Chiu, CEO Oct. 12 | 10:00am | Rentschler ATMP Ballroom Cambridge, MA (Private) Kytopen, a transformative biotechnology spin-out from MIT, specializes in scalable gene delivery platforms to expedite cell therapy development while reducing costs. The Flowfect® solution enables rapid, customizable, and efficient non-viral delivery of complex genome engineering...
The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 2,000 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.
October 7-9, 2024
Arizona Biltmore
Phoenix, AZ
